US Stock Insider Trading | Caris Life Sciences disclosed 1 insider transaction on March 2

K-LinePoet · 2026-03-10T12:34:03+00:00

Caris Life Sciences disclosed on March 2, 2026, that director Minor Lloyd purchased 2,492 shares on February 26, demonstrating ongoing interest from company insiders in the stock. The company focuses on leveraging AI and molecular information to provide precision medical solutions and promote healthcare development.

K-LinePoet

2026-03-10 12:34:03

Abstract generation in progress

On March 2, 2026, Caris Life Sciences (CAI) disclosed an insider transaction. Director Minor Lloyd purchased 2,492 shares on February 26, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 2, 2026	Director	Minor Lloyd	February 26, 2026	Buy	2,492	20.06	$50,000
February 27, 2026	Director	CASTLEMAN PETER M, Fredrickson David Paul, HALBERT JON, PHILLIPS T DANNY, Vacirca Jeff L	February 26, 2026	Buy	16,700	20.06	$335,500
January 13, 2026	Director	CASTLEMAN PETER M	January 9, 2026	Buy	2,500	18.60	$46,500
December 12, 2025	Executive	Power Luke Thomas	December 11, 2025	Sell	60,900	26.56	$1,616,400
December 12, 2025	Executive	Power Luke Thomas	December 11, 2025	Buy	62,300	2.44	$151,900
December 12, 2025	Executive	Power Luke Thomas	December 11, 2025	Sell	1,400	27.16	$38,000
November 10, 2025	Executive	Denton John Russel	November 7, 2025	Buy	4,184	24.09	$100,800
November 10, 2025	Executive	Spetzler David Baxley	November 7, 2025	Buy	400	23.85	$9,540
September 12, 2025	Director	PHILLIPS T DANNY	September 11, 2025	Buy	100,000	2.44	$244,000
August 13, 2025	Shareholder with >10%	HALBERT DAVID D	August 11, 2025	Sell	142,000	29.75	$4,223,200

[Company Information]

Caris Life Sciences, Inc. was incorporated in the Cayman Islands in November 2011 and re-registered in Texas in July 2020, headquartered in Irving, Texas. They are a leading patient-centric next-generation AI biotech company and pioneer in precision medicine. They develop and commercialize innovative solutions that leverage large-scale integrated molecular information and AI/machine learning algorithms to transform healthcare. Their comprehensive precision medicine portfolio aims to benefit patients, initially focusing on oncology, serving clinical, academic, and biopharmaceutical markets.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.